1. Home
  2. TRIB vs BCDA Comparison

TRIB vs BCDA Comparison

Compare TRIB & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRIB

Trinity Biotech plc

HOLD

Current Price

$0.71

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.12

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIB
BCDA
Founded
1992
N/A
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4M
14.5M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
TRIB
BCDA
Price
$0.71
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
167.2K
53.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.51
N/A
Revenue Next Year
$13.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$1.00
52 Week High
$3.44
$3.20

Technical Indicators

Market Signals
Indicator
TRIB
BCDA
Relative Strength Index (RSI) 40.36 36.66
Support Level $0.68 $1.00
Resistance Level $0.80 $1.33
Average True Range (ATR) 0.07 0.08
MACD -0.01 -0.01
Stochastic Oscillator 28.31 10.42

Price Performance

Historical Comparison
TRIB
BCDA

About TRIB Trinity Biotech plc

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: